VCHRI hosted the N2 Canada Western Regional Meeting, bringing together clinical research leaders and community and industry partners to explore how collaboration, equity and innovation can advance clinical trials and improve patient access to research.
British Columbia is home to world-class research expertise, leading health care institutions and a strong network of clinical research partners. Collaboration is essential to advancing clinical trials, accelerating the development of new therapies and expanding access to research for patients and communities.
On November 6, 2026, Vancouver Coastal Health Research Institute (VCHRI) was proud to host the Network of Networks (N2) Western Regional Meeting, welcoming clinical research leaders and partners from across B.C. and Western Canada to explore opportunities and challenges shaping the future of clinical trials.
Researchers, clinicians, health system leaders, industry partners and people with lived experience came together for a day of discussion and knowledge exchange. The program highlighted four key priorities: meaningful patient and community engagement, advancing equity in research, strengthening partnerships and leveraging technology to improve the clinical trials environment.

Partnerships and innovation shaping the future of clinical trials
Meaningful patient and community engagement is essential to designing clinical trials that reflect the needs and experiences of the people they aim to serve. Discussions explored how involving people with lived experience from the earliest stages of research can help shape more relevant research questions, improve trial design and make participation more accessible.

Strengthening early-phase clinical trial capacity is an essential step in translating scientific discoveries into new treatments that can make a meaningful difference in patient care. Discussions highlighted the importance of strong clinical partnerships and specialized infrastructure, including the Phase 1 Clinical Trials Research Unit at VCH, in advancing emerging therapies and creating new opportunities for complex early-phase research in B.C.

A session on equity highlighted the importance of inclusive research approaches, building meaningful relationships with communities and addressing barriers to participation. Speakers emphasized the need to incorporate Indigenous perspectives and culturally responsive engagement throughout the research process to ensure clinical trials better reflect the diversity of the populations they serve.

A panel exploring accelerating digital technologies and health data showcased how these themes have become critical drivers of a more connected and efficient clinical trials ecosystem. Speakers touched on how integrated data platforms, digital tools and stronger health system partnerships can streamline research processes, support collaboration across institutions and create new opportunities to accelerate clinical trials.

Building B.C.'s clinical trials infrastructure
As B.C.'s leading research institute, VCHRI is well positioned to help advance the province's clinical trials agenda. Its strength lies in bringing together the expertise and capabilities needed to advance clinical research, including internationally recognized investigators, specialized clinical teams, established clinical trials programs, research support services, health system infrastructure and meaningful patient and community partnerships.
VCHRI is also investing in the next generation of clinical trials infrastructure through the development of its Phase 1 Clinical Trials Research Unit at UBC Hospital. The new unit will expand B.C.'s capacity to conduct first-in-human and complex early-phase trials within an integrated hospital environment, connecting emerging therapies with specialized clinical expertise, research-trained teams and hospital resources.

The N2 Western Regional Meeting reinforced a shared ambition: to build a clinical trials ecosystem that is more inclusive, collaborative and responsive, translating B.C.'s research strengths into meaningful benefits for patients and communities.
VCHRI thanks N2, Clinical Trials British Columbia and all participating speakers, moderators, patient partners and attendees for their contributions and continued commitment to advancing clinical research.